COPENHAGEN (Reuters) - Novo Nordisk plans to invest up to 20 billion Danish crowns ($3.65 billion) on developing diabetes tablets intended to replace traditional insulin injections, it said on Monday.
A world-first clinical trial has found that baricitinib, a drug commonly prescribed for rheumatoid arthritis, preserved the pancreatic cells’ ability to produce their own insulin and slowed the ...
WellCare of Kentucky and Centene Foundation, the philanthropic arm of Centene Corp., today announced an investment of $550,000 to launch the WellCare Food is Medicine Program to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results